
Notice to Comply

Application No.	Applicant(s)	
10/774,721	Jockers et al.	
Examiner Louis V. Wollenberger	Art Unit 1635	



NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE BISCLOSURES

Applicant must file the items indicated below within the time period set in the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):
☑ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/o 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
7. Other: Sequences in drawing figures 1, 2, and 11A lack SEQ ID NO: identifiers. Identifiers must appear in the drawings themselves or in the descriptions of the drawings in the specification.
Applicant Must Provide: An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
An <u>initial</u> or substitute paper copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the application.
A statement that the content of the paper and computer readable copies are the same and, when applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
For questions regarding compliance to these requirements, please contact:
For Rules Interpretation, call (571) 272-2510 For CRF Submission Help, call (571) 272-2501/2583. Patentin Software Program Support
Technical Assistance703-287-0200 To Purchase Patentin Software703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of JOCKERS et al.

Application No.: 10/774,7

Filed:

February 9, 2004

Title: OLIGONUCLEOTIDES WHICH INHIBIT

MAR 1 0 2006

EXPRESSION OF THE OB-RGRP PROTEIN AND **DETECTING COMPOUNDS METHOD FOR WHICH MODIFY INTERACTION** THE BETWEEN PROTEINS THE OB-RGRP OF FAMILY AND THE LEPTIN RECEPTOR

Examiner: Wollenberger, Louis

Art Unit:

1635

Certificate of Mailing or Transmission

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop address below, or being facsimile transmitted to the

USPTO, on the date indicated below.

Date of Deposit Printed Name of Person Signing Certificate 72

Signature

STATEMENT REGARDING CONTENT OF PAPER AND COMPUTER READABLE COPIES PURSUANT TO 37 C.F.R. 1.821 (f)

Mail Stop Sequence Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

The undersigned states that the content of the nucleotide and/or amino acid sequences set forth in the enclosed substitute pages of the "Sequence Listing" and the computer readable copies required by 37 C.F.R. 1.821 (e) submitted herewith are the same; and (2) the content of the substitute copy of the Sequence Listing and the computer readable copies required by 37 C.F.R. 1.821 (e) contain no new matter. Support for the Amendments can be found in the application as filed.

Respectfully submitted,

George S. Jones, Reg. No. 38,508

Attorney/Agent for Applicant

sanofi-aventis Inc. LLC U.S. Patent Operations Route #202-206 / P.O. Box 6800 Bridgewater, New Jersey 08807-0800 Telephone (908) 231-3776 (908) 231-2626 Telefax

sanofi-aventis Docket No. FRAV2003/0005 US NP